Nutex Health Inc Dossier - Source-backed chat

Nutex Health Inc

NUTXNASDAQ

SectorHealth Care

IndustryMedical Care Facilities

Beta (adjusted)1.63

Intrinsic Value $782.57median of 6 methods · middle span $139-$3,032based on filings through 30 Jun 2026

Market Price $212.31Price as of 1 Oct 2026

Significantly undervaluedIntrinsic value is 269% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

marker beyond scale (+269%)

Data confidence Sign in to view data confidence

Market Cap $1.5B

Enterprise Value $1.3B

Shares Outstanding 7.5M diluted

Moat Rating Wide

Next Earnings Date13 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Nutex Health, Inc. (NASDAQ: NUTX) has demonstrated a significant turnaround in profitability, driven by strong performance in its hospital division and favorable outcomes in the Independent Dispute Resolution (IDR) process under the No Surprises Act. However, the company's organic same-hospital growth remains stagnant, and its business model is highly dependent on out-of-network reimbursement and complex arbitration processes. While its balance sheet is robust with substantial cash reserves, the high regulatory and collection risks warrant a cautious Hold recommendation.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets5 analysts · as of 18 Aug 2026

Low · most bearish analyst$200.00

Mean target$266.40

High · most bullish analyst$310.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

Regulatory shifts or legal challenges to the No Surprises Act framework disrupt the IDR process, leading to lower win rates or collection delays. Arbitration costs escalate further, and stagnant organic patient volumes fail to offset the decline in out-of-network reimbursement, severely pressuring margins and cash flow.

Base CaseCentral scenario

The company continues to successfully navigate the IDR process, maintaining high win and collection rates. Selective self-development of new facilities supports moderate top-line expansion, while same-hospital volumes remain relatively flat. Profitability is sustained but constrained by high arbitration-related costs.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong balance sheet with record cash reserves of $207.3 million and low leverage as of Q1 2026.
Strong earnings growth forecast, with earnings expected to grow by 31.2% per annum and EPS expected to grow by 23.6% per annum.
Active capital return program, including significant share repurchases to offset dilution.

Key Investment Risks

Extreme concentration of revenue tied to out-of-network billing and the federal No Surprises Act arbitration process.
Stagnant organic growth, with same-hospital revenue increasing only 0.2% and same-hospital visits up 0.6% in Q1 2026.
Potential headwinds from rising labor costs and regulatory changes that could impact margins.

Thesis Invalidation Triggers

A material decline in the IDR win rate or collection rate that significantly impacts out-of-network revenue.
Adverse regulatory changes to the No Surprises Act or Independent Dispute Resolution rules that limit out-of-network reimbursement.
A significant drop in cash reserves or failure to improve cash flow due to delayed arbitration collections or escalating dispute costs.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.